Skip to main content

Advertisement

Table 2 Summary of efficacy outcomes

From: S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial

  ITT population ( n= 49)
Endpoints n (%)
pCR* in breast and AXLN 11 (22.5%)
pCR* in breast 15 (30.6%)
Clinical response   
   Complete response 6 (12.3)
   Partial response 27 (55.1)
   Stable disease 14 (28.6)
   Progressive disease 1 (2.0)
   Non-assessable 1 (2.0)
Breast-conserving surgery   
   Yes 21 (42.9)
   No 26 (53.1)
   Non-assessable 2 (4.0)
  1. ITT, intent-to-treat; pCR, pathological complete response; *pCR was defined as the absence of invasive disease.